130 related articles for article (PubMed ID: 2311444)
1. Transintestinal elimination of ciprofloxacin.
Rohwedder R; Bergan T; Thorsteinsson SB; Scholl H
Chemotherapy; 1990; 36(2):77-84. PubMed ID: 2311444
[TBL] [Abstract][Full Text] [Related]
2. Transintestinal elimination of ciprofloxacin.
Rohwedder RW; Bergan T; Thorsteinsson SB; Scholl H
Diagn Microbiol Infect Dis; 1990; 13(2):127-33. PubMed ID: 2369809
[TBL] [Abstract][Full Text] [Related]
3. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
[TBL] [Abstract][Full Text] [Related]
4. An overview of the pharmacology of intravenously administered ciprofloxacin.
Drusano GL
Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.
Bergan T
J Chemother; 1989 Feb; 1(1):10-7. PubMed ID: 2542469
[TBL] [Abstract][Full Text] [Related]
6. Comparative pharmacokinetics of intravenous ofloxacin and ciprofloxacin.
Lode H; Höffken G; Olschewski P; Sievers B; Kirch A; Borner K; Koeppe P
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():73-9. PubMed ID: 3182465
[TBL] [Abstract][Full Text] [Related]
7. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
Yu H; Wang HY; Sun ZM
Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
[TBL] [Abstract][Full Text] [Related]
8. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, renal clearance and metabolism of ciprofloxacin following intravenous and oral administration to calves and pigs.
Nouws JF; Mevius DJ; Vree TB; Baars AM; Laurensen J
Vet Q; 1988 Jul; 10(3):156-63. PubMed ID: 3176294
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of iopentol in patients with chronic renal failure.
Svaland MG; Kolmannskog F; Lillevold PE; Nordal KP; Ressem L; Berg KJ
Acta Radiol; 1992 Sep; 33(5):482-4. PubMed ID: 1389660
[TBL] [Abstract][Full Text] [Related]
12. Disposition of ciprofloxacin following intravenous administration in dogs.
Abadía AR; Aramayona JJ; Muñoz MJ; Pla Delfina JM; Saez MP; Bregante MA
J Vet Pharmacol Ther; 1994 Oct; 17(5):384-8. PubMed ID: 7853464
[TBL] [Abstract][Full Text] [Related]
13. Transintestinal elimination of ciprofloxacin in humans--concomitant assessment of its metabolites in serum, ileum and colon.
Viell B; Krause B; Vestweber KH; Schaaf S; Scholl H
Infection; 1992; 20(6):324-7. PubMed ID: 1293050
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
[TBL] [Abstract][Full Text] [Related]
15. Elimination of furosemide in healthy subjects and in those with renal failure.
Beermann B; Dalén E; Lindström B
Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
[TBL] [Abstract][Full Text] [Related]
16. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
17. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
Prescott LF; Freestone S; McAuslane JA
Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
[TBL] [Abstract][Full Text] [Related]
18. Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin.
Garraffo R; Dellamonica P; Bernard E; Etesse H; Lapalus P
Int J Clin Pharmacol Res; 1989; 9(1):29-35. PubMed ID: 2707923
[TBL] [Abstract][Full Text] [Related]
19. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses.
Nix DE; Spivey JM; Norman A; Schentag JJ
Ann Pharmacother; 1992 Jan; 26(1):8-10. PubMed ID: 1606348
[TBL] [Abstract][Full Text] [Related]
20. Intravenous ciprofloxacin disposition in obesity.
Allard S; Kinzig M; Boivin G; Sörgel F; LeBel M
Clin Pharmacol Ther; 1993 Oct; 54(4):368-73. PubMed ID: 8222478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
